BIOIMAGE-NMD

BIOIMAGE-Neuromuscular Diseases

 Coordinatore UNIVERSITY OF NEWCASTLE UPON TYNE 

 Organization address address: Kensington Terrace 6
city: NEWCASTLE UPON TYNE
postcode: NE1 7RU

contact info
Titolo: Mrs.
Nome: Helen
Cognome: Gallon
Email: send email
Telefono: +44 0 1912824513

 Nazionalità Coordinatore United Kingdom [UK]
 Totale costo 7˙838˙853 €
 EC contributo 5˙960˙532 €
 Programma FP7-HEALTH
Specific Programme "Cooperation": Health
 Code Call FP7-HEALTH-2013-INNOVATION-1
 Funding Scheme CP-FP
 Anno di inizio 2013
 Periodo (anno-mese-giorno) 2013-10-01   -   2017-03-31

 Partecipanti

# participant  country  role  EC contrib. [€] 
1    UNIVERSITY OF NEWCASTLE UPON TYNE

 Organization address address: Kensington Terrace 6
city: NEWCASTLE UPON TYNE
postcode: NE1 7RU

contact info
Titolo: Mrs.
Nome: Helen
Cognome: Gallon
Email: send email
Telefono: +44 0 1912824513

UK (NEWCASTLE UPON TYNE) coordinator 1˙452˙729.20
2    BIOMARIN NEDERLAND BV

 Organization address address: J H OORTWEG 21
city: LEIDEN
postcode: 2333 CH

contact info
Titolo: Dr.
Nome: Isabel
Cognome: Ferreira
Email: send email
Telefono: 31614790205
Fax: 31713322088

NL (LEIDEN) participant 1˙128˙014.00
3    ASSOCIATION INSTITUT DE MYOLOGIE

 Organization address address: BOULEVARD DE L HOPITAL 47-83
city: PARIS
postcode: 75651

contact info
Titolo: Mrs.
Nome: Christelle
Cognome: Gaultier
Email: send email
Telefono: +33 14216 66 46

FR (PARIS) participant 1˙044˙498.00
4    UNIVERSITY COLLEGE LONDON

 Organization address address: GOWER STREET
city: LONDON
postcode: WC1E 6BT

contact info
Titolo: Ms.
Nome: Gosia
Cognome: Kielbasa
Email: send email
Telefono: +44 2031083033
Fax: +44 20 78132849

UK (LONDON) participant 591˙293.00
5    SCITO SA

 Organization address address: RUE DES HAIES 8
city: PARIS
postcode: 75020

contact info
Titolo: Dr.
Nome: Arno
Cognome: Klaassen
Email: send email
Telefono: +33 971279191

FR (PARIS) participant 571˙266.80
6    ACADEMISCH ZIEKENHUIS LEIDEN

 Organization address address: Albinusdreef 2
city: LEIDEN
postcode: 2333 ZA

contact info
Titolo: Prof.
Nome: Jan
Cognome: Verschuuren
Email: send email
Telefono: +31 715262197

NL (LEIDEN) participant 531˙492.00
7    CONSULTANTS FOR RESEARCH IN IMAGING AND SPECTROSCOPY SCRL

 Organization address address: RUE LOUIS JAMME 24
city: LIEGE
postcode: 4020

contact info
Titolo: Dr.
Nome: Raymond
Cognome: Gilles
Email: send email
Telefono: +31 14790205

BE (LIEGE) participant 399˙800.00
8    KATHOLIEKE UNIVERSITEIT LEUVEN

 Organization address address: Oude Markt 13
city: LEUVEN
postcode: 3000

contact info
Titolo: Dr.
Nome: Elke
Cognome: Lammertyn
Email: send email
Telefono: +32 16 32 06 21

BE (LEUVEN) participant 120˙720.00
9    UNIVERSITA CATTOLICA DEL SACRO CUORE

 Organization address address: Largo Agostino Gemelli 1
city: MILANO
postcode: 20123

contact info
Titolo: Mr.
Nome: Filippo
Cognome: Leone
Email: send email
Telefono: +39 0630156099

IT (MILANO) participant 120˙720.00

Mappa


 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

nmd    imaging    muscle    magnetic    disease    resonance    treatment    bioimage    mrsi    pet    diseases    protocol    clinical    therapy    mri    therapeutic    aon    trials    dmd   

 Obiettivo del progetto (Objective)

'BIOIMAGE-NMD will develop and apply imaging technology to monitor response to novel therapies in neuromuscular diseases (NMD) and will use Duchenne muscular dystrophy (DMD) as an exemplar disease. DMD is well characterised genetically and clinically but to date a disease modifying treatment is not available. One of the most promising developments for future treatment of NMD is RNA modulation through antisense oligonucleotides (AON). In DMD, AON are used for exon skipping and this is a genuine example of personalised medicine, where patients are treated according to their specific gene mutation. Quantitative Magnetic Resonance Imaging (MRI) and Magnetic Resonance Spectroscopic Imaging (MRSI) are used to assess structural and metabolic muscle pathology in NMD but their effectiveness in monitoring therapy is yet to be shown. The project will apply a simultaneous MRI/MRSI protocol in multi-centre clinical trials of AON therapy in DMD with the aim of establishing a clinical proof of principle that these imaging measures are effective biomarkers of therapeutic response. To enhance the imaging protocol, novel Diffusion Tensor MRI (DTI) methods will be developed and optimised to assess muscle microstructure and applied in these trials. The project will also develop methods for radiolabelling of AON and demonstrate the use of pre-clinical Positron Emission Tomography (PET)/MRI to assess the tissue targeting, bio-distribution and pharmacokinetics of AON in vivo. BIOIMAGE-NMD will deliver PET/MRI and MRI/MRSI technologies for both drug development and clinical evaluation roles which will significantly contribute to bringing personalized therapeutic interventions in rare and common diseases to the market.'

Altri progetti dello stesso programma (FP7-HEALTH)

MUTHI (2011)

Multi-disciplinary University Traditional Health Initiative (MUTHI): Building Sustainable Research Capacity on Plants for Better Public Health in Africa

Read More  

IPODD (2008)

IBD: proteases offer new targets for drug discovery

Read More  

NGIN (2008)

Next Generation HIV-1 Immunogens inducing broadly reactive Neutralising antibodies

Read More